Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.
Solaymani-Dodaran M, Ghanei M, Bagheri M, Qazvini A, Vahedi E, Hassan Saadat S, Amin Setarehdan S, Ansarifar A, Biganeh H, Mohazzab A, Khalili D, Hosein Ghazale A, Reza Heidari M, Taheri A, Khoramdad M, Mahdi Asadi M, Nazemieh M, Varshochi M, Abbasian S, Bakhtiari A, Mosaed R, Hosseini-Shokouh SJ, Shahrokhi M, Yassin Z, Ali Zohal M, Qaraati M, Rastgoo N, Sami R, Javad Eslami M, Asghari A, Namazi M, Ziaie S, Jafari-Moghaddam R, Kalantari S, Memarian M, Khodadadi J, Hossein Afshari M, Momen-Heravi M, Behzadseresht N, Reza Mobayen A, Mozafari A, Movasaghi F, Haddadzadeh Shoushtari M, Moazen J.
Solaymani-Dodaran M, et al. Among authors: mohazzab a.
Int Immunopharmacol. 2021 Jun;95:107522. doi: 10.1016/j.intimp.2021.107522. Epub 2021 Mar 11.
Int Immunopharmacol. 2021.
PMID: 33735712
Free PMC article.
Clinical Trial.